Who is eligible for clinical trial NCT06751992?

Participants must meet protocol criteria for Kidney Transplant Recipients. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06751992 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-05-26

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients (NCT06751992)

Neurocognitive Function Changes With Once-Daily Extended-Release Tacrolimus (Envarsus XR) Conversion Compared to Twice-Daily Immediate Release Tacrolimus Maintenance Among Older Kidney Transplant Recipients

🟢 Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: Massachusetts General Hospital

🩺 Plain-English Summary (8th-Grade Level)

The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).

Who can join: Review the eligibility criteria below.

Location: MGH Kidney Transplant Clinic — Boston, Massachusetts

Age range: 65 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

MGH Kidney Transplant Clinic — Boston, Massachusetts

📞 Contact the Study Coordinator

Phone: (617) 724-0345

Email: lriella@mgh.harvard.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Kidney Transplant Recipients

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients — Toronto, Ontario
Velocity-Based Resistance Training in Kidney Transplant Recipients — Bogotá, Bogota D.C.

Explore by condition: All Kidney Transplant Recipients clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗